3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Chevron agreed to transfer its ownership interests and general partner position in Hess Midstream LP, plus its DJ Basin crude oil midstream assets, in exchange for extended Bakken midstream contracts, new DJ Basin contracts and $200 million in cash. Chevron expects a one-time after-tax loss of approximately $3 to $4 billion at closing, which it expects to treat as a special item, and expects the deal to close by year-end 2026.
At closing, Chevron expects a one-time after-tax loss of approximately $3 to $4 billion, treated as a special item.
Chevron expects to reduce its Bakken unit midstream costs by approximately 50% and to increase return on capital employed.
Chevron receives $200 million in cash and expects to fully deconsolidate Hess Midstream, including about $3.7 billion of its debt.
The deal is expected to close by year-end 2026, subject to customary closing conditions and regulatory approvals.
Rocket Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on September 30, 2026, providing up to $150.0 million in senior secured term loans, with $35.0 million funded at closing. The company also issued warrants to the lenders for 1,755,853 shares of common stock at $2.99 per share, which adds potential dilution, and the loans are secured by substantially all of the company's assets.
Tranche 1-A advance of $35.0 million funded September 30, 2026; further tranches total up to $115.0 million at the company's option or the lenders' approval
Loans mature October 1, 2030, with interest at the greater of prime or 6.75%, plus 2.40%
Warrants for 1,755,853 shares at $2.99 per share; 409,699 shares exercisable after the Tranche 1-A funding
Prepayment charges of 3.00%, 2.00% or 1.00% depending on timing; minimum cash covenant not tested while market capitalization exceeds $600.0 million
Fair Isaac committed on October 1, 2026 to a workforce reduction that eliminates about 15% of its positions, while reducing management layers, simplifying its operating structure, and integrating AI-driven product development. The company expects aggregate pre-tax charges of about $27.0 million in the fourth quarter of fiscal 2026, mostly severance, and the plan is expected to be substantially complete by the end of the third quarter of fiscal 2027.
About 15% of positions across the company will be eliminated.
Expected pre-tax charges of approximately $27.0 million in Q4 fiscal 2026, mainly employee severance and related costs.
Affected employees began being notified the week of October 5, 2026.
Plan expected to be substantially completed by the end of Q3 fiscal 2027.
At a special meeting on October 6, 2026, stockholders approved raising authorized common stock from 250,000,000 to 275,000,000 shares and approved issuing common stock on conversion of Series C preferred stock and warrants, which the filing says could exceed 20% of outstanding shares and may, with management and board changes, result in a change of control. The filing body names Quince Therapeutics, Inc. while the header lists IRulya Therapeutics Inc., so the registrant identity should be confirmed. For shareholders, the approvals add capacity for potential dilution and a possible change in control.
Authorized common stock increased from 250,000,000 to 275,000,000 shares, effective October 6, 2026
Proposal 2 passed with 343,517 votes for and 5,759 against; Proposal 1 passed with 180,550 votes for and 5,742 against
Proposal 1 may result in a change of control under Nasdaq Listing Rule 5635(b)
2026 Equity Incentive Plan reserve starts at 821,872 shares; 2026 ESPP reserve starts at 142,045 shares
BeyondSpring completed the sale of BeyondSpring Ltd., which indirectly holds its interest in Bulin, to Biolin Investment Limited on September 30, 2026. The Company received no cash; the buyer's consideration is a commitment to fund the China portion of the DUBLIN-4 Phase 3 trial and a license to the resulting data. The Company no longer controls the disposed entities or SEED Therapeutics, and the pro forma figures show a preliminary gain of $53.7 million that is not yet final.
No cash consideration was paid or payable at closing on September 30, 2026
Non-cash consideration: the Investor's obligation to fund and complete the China portion of DUBLIN-4, plus a license to the trial data
Preliminary pro forma gain on disposition of $53.7 million (about $53,677 thousand); excludes contingent consideration and may differ materially
After the sale, the Company retained about 29% of SEED's voting power on an as-converted basis but no control of SEED
AXIL Brands reported first-quarter fiscal 2027 results for the three months ended August 31, 2026. Revenue fell 11.2% to $6.1 million from $6.9 million, while net income rose to $0.4 million, or $0.05 per diluted share, helped by a non-recurring $0.55 million customs duty refund. Management said XCOR II orders of $3.6 million through September 30 should show up in second-quarter revenue.
Net revenues were $6.1 million, down 11.2% from $6.9 million, reflecting the XCOR to XCOR II transition and a prior-year big-box order that did not repeat.
Net income was $0.4 million, or $0.05 per diluted share, compared with $0.3 million, or $0.04 per diluted share a year earlier.
Gross margin of 82.6% included a $0.55 million IEEPA customs duty refund; excluding it, gross margin was approximately 73.6%.
XCOR II orders exceeded $3.6 million as of September 30, 2026, and cash was $7.9 million with no outstanding borrowings.
AMASS Brands reported preliminary, unaudited third-quarter 2026 net revenue of approximately $5.3 million, up about 30% from $4.1 million a year earlier and about 20% above its guidance of at least $4.4 million. Gross profit, operating expenses and Adjusted EBITDA have not been completed, and the company's forward-looking statements cite substantial doubt about its ability to continue as a going concern and its need to raise additional capital.
Revenue exceeded the company's third-quarter guidance of at least $4.4 million by about 20%
Core brand net revenue of approximately $3.8 million, up 67%; Non-Alcoholic and Functional segment revenue of approximately $0.6 million, supported by the May 2026 launch of AMASS Electrolytes
Full third-quarter results expected after market close on or before November 16, 2026; the filing cites substantial doubt about the company's ability to continue as a going concern
Rocky Mountain Chocolate Factory agreed to sell its Durango, Colorado property, which serves as its corporate headquarters and production and warehouse facility, to American Heritage Legacies, LLC for $6.6 million, and will lease it back for 10 years. The buyer is controlled by the family of Interim CEO Allen Harper, making the deal a related party transaction, and proceeds will repay $6.6 million of notes at 12% annual interest held by entities affiliated with board members Steven L. Craig and Jeffrey R. Geygan, which reduces debt but commits the company to rent and a possible buyback obligation if control changes.
Sale price is $6.6 million; closing is expected on or about October 15, 2026, with an independent appraisal supporting the price
Net proceeds are expected to repay $6.6 million of notes accruing 12% per annum, held by RMC Credit Facility LLC and RMCF2 Credit, LLC
Lease has a 10-year initial term, first-year annual rent of $624,000 rising 2% a year, and an option to renew for 10 more years
On a change of control, the lease terminates and, at the landlord's option, the company must buy back the property for the greater of $6.93 million or appraised value
Saratoga Investment reported fiscal second-quarter 2027 results for the period ended August 31, 2026, showing a loss of $0.41 per share, compared with earnings of $0.84 a year earlier. Net asset value per share fell to $22.15 from $23.23 in the prior quarter, while total investment income rose 2.0% year over year to $31.2 million. The results matter to shareholders because the NAV decline reflects portfolio markdowns and dividends above earnings, while the $0.75 per share quarterly dividend was unchanged.
Earnings per share were $(0.41), versus $(0.42) in the prior quarter and $0.84 a year earlier.
NAV per share fell to $22.15 from $23.23 on May 31, 2026; total NAV was $352.6 million, down $25.9 million for the quarter.
Adjusted net investment income was $0.46 per share, compared with $0.47 last quarter; total investment income was $31.2 million.
The company repurchased 444,124 shares at an average price of $18.91 and declared a $0.75 per share dividend for the third quarter of fiscal 2027.
Neighborhood Intelligence sold about 10.9 million common shares plus pre-funded and common warrants in a registered direct offering that closed October 6, 2026, with approximately $42.6 million in net proceeds. The company also cut its at-the-market program ceiling from $200 million to $75 million, and its Executive Chairman and CEO bought shares at the same $2.76 price, so the offering adds share count and potential dilution for existing holders.
Offering of 10,881,192 common shares at $2.76 per share, plus pre-funded warrants for 5,241,997 shares and common warrants for 16,123,189 shares, closed October 6, 2026.
Net proceeds of approximately $42.6 million, which the company intends to use to accelerate merger synergies and build inventory.
Maximum aggregate offering price under the at-the-market program reduced from $200,000,000 to $75,000,000 on October 5, 2026.
Company and directors and executive officers agreed to lock-ups of 90 days after closing; Marcus Lemonis bought 362,319 shares at $2.76.
Neogen reported first-quarter fiscal 2027 revenue of $222.8 million, up 6.5% from a year earlier, and raised its fiscal 2027 revenue and Adjusted EBITDA guidance. The company still posted a GAAP net loss of $11.9 million, compared with net income of $36.3 million a year earlier, when a $76.4 million gain on the sale of a business boosted results.
Revenue of $222.8 million vs. $209.2 million a year earlier; core revenue growth of 8.1%
Net loss of $11.9 million, or $(0.05) per diluted share, vs. net income of $36.3 million, or $0.17, a year earlier; Adjusted EPS was $0.08 vs. $0.04
Fiscal 2027 revenue guidance raised to $885 million to $890 million from $880 million to $885 million; Adjusted EBITDA guidance raised to $181 million to $183 million from $180 million to $182 million
Pending sale of the Genomics business to Zoetis Inc. is expected to conclude regulatory reviews by the end of December 2026
Brandywine Realty Trust completed the sale of its interest in a 441,000 square foot Philadelphia office building at 3151 Market Street on September 30, 2026, for a sales price of $240.0 million and net proceeds of approximately $233.7 million. The company repaid $60.2 million, including retirement of a $57.3 million C-PACE loan that encumbered the property. Pro forma filings show a 2025 net loss per share of $1.17 versus $1.03 as reported, and a six-month 2026 loss per share of $0.43 versus $0.46, though the company says actual charges may differ materially.
Sales price of $240.0 million and net proceeds of approximately $233.7 million, completed September 30, 2026
$60.2 million repaid, including retirement of the $57.3 million C-PACE loan encumbering the property
Pro forma basic loss per share for 2025 was $1.17 versus $1.03 reported; for the six months ended June 30, 2026, it was $0.43 versus $0.46 reported
Pro forma adjustments include a $23.6 million provision for impairment and $6.3 million loss on early extinguishment of debt, which may differ from actual amounts
Apogee Enterprises reported fiscal second-quarter 2027 net sales up 9.2% to $391.1 million and adjusted diluted EPS of $1.17, up from $0.98. GAAP diluted EPS fell 2.7% to $1.07 and net earnings fell 5.4%. The company raised its fiscal 2027 adjusted diluted EPS guidance to $3.00-$3.40 from $2.70-$3.25, which matters to shareholders because it reflects higher expected earnings, though GAAP profit declined in the quarter.
Q2 net sales rose 9.2% to $391.1 million, including a $16.4 million contribution from the Kalwall acquisition
Q2 GAAP diluted EPS was $1.07 versus $1.10; net earnings were $22.4 million versus $23.6 million
Q2 adjusted diluted EPS was $1.17 versus $0.98, a 19.4% increase
Fiscal 2027 net sales guidance raised to $1.46 billion-$1.50 billion from $1.38 billion-$1.43 billion
Skydance Corporation, formerly Paramount Skydance, completed its acquisition of Warner Bros. Discovery on October 6, 2026, and began trading as SKYD on the NYSE under the new name. The company issued $41.4 billion of senior secured notes on October 5 to help finance the deal, and the filing estimates total cash consideration to WBD shareholders at $78.0 billion, so the transaction adds substantial debt and share issuance for existing shareholders.
WBD shareholders receive $31.00 per share in cash plus ticking consideration; the press release cites $31.01666668 per share
Company issued $41.4 billion of senior secured notes on October 5, 2026, including $30.0 billion first lien and $11.4 billion second lien dollar notes plus €885 million euro notes
Equity investors bought about 3,918 million new Class B shares at $12.00 per share
Management targets at least $6 billion in run-rate synergies within three years and net leverage of 3.0x by the end of 2029
HubSpot's board authorized a restructuring plan on October 1, 2026 that eliminates certain roles, affecting about 7% of the workforce; the CEO's employee memo says nearly 660 people will leave. The company estimates $65 million to $75 million in charges, mostly recognized in the fourth quarter of fiscal 2026, and will exclude them from non-GAAP results, while reaffirming its third-quarter and full-year 2026 revenue, non-GAAP operating income and non-GAAP EPS guidance.
Board authorized the plan on October 1, 2026; it affects about 7% of the workforce, and the CEO's memo cites nearly 660 employees.
Estimated charges of $65 million to $75 million, mainly severance, notice period, employee transition and benefits payments.
Majority of charges expected in fourth quarter 2026; role eliminations substantially complete by end of first quarter 2027; substantially all cash payments by June 30, 2027.
Company reaffirmed third-quarter 2026 and fiscal 2026 revenue, non-GAAP operating income and non-GAAP EPS guidance.
Lamb Weston reported fiscal first-quarter 2027 net sales up 1% to $1.67 billion, but reported net income fell 55% to $29 million and diluted EPS fell to $0.21 from $0.46. The company raised its full-year fiscal 2027 adjusted diluted EPS outlook to $3.05 to $3.35 from $2.95 to $3.25, and its adjusted EBITDA outlook to $1.125 billion to $1.215 billion from $1.10 billion to $1.20 billion.
Q1 net sales rose 1% to $1.67 billion; North America sales rose 5% while International sales fell 8%.
Reported diluted EPS was $0.21 versus $0.46 a year earlier; adjusted diluted EPS was $0.75 versus $0.74.
Adjusted EBITDA was $286 million, down 5%; International segment Adjusted EBITDA fell 54% to $27 million.
Fiscal 2027 adjusted diluted EPS outlook raised to $3.05 to $3.35; the company did not repurchase shares in the quarter and $245 million remains authorized for buybacks.
B&G Foods and Nortera Foods mutually terminated their October 24, 2025 agreement to sell Green Giant Canada after Canadian regulatory approval under the Competition Act was not obtained by the September 24, 2026 outside date. B&G Foods will keep owning and operating Green Giant Canada and says it will continue evaluating alternatives, including potential sales, for the business.
Agreement terminated October 5, 2026; Competition Act approval not obtained by the September 24, 2026 outside date
Nortera Foods will pay B&G Foods US$1.6 million, covering a termination fee and part of B&G Foods' legal expenses
Nortera Foods will continue as primary co-manufacturer for Green Giant Canada
B&G Foods intends to evaluate strategic and operational alternatives for Green Giant Canada, including potential sales
Telomir Pharmaceuticals sold 4,843,300 shares of common stock at $1.16 per share in a private placement that closed on October 5, 2026, for approximately $5.6 million in gross proceeds before expenses. The company said it will use the proceeds mainly to support clinical development of Telomir-Zn, including its Phase 1/2 trial in advanced or metastatic triple-negative breast cancer, and for working capital. The new shares add to the existing share count and carry a placement agent fee and warrants, and the company must register the resale of the shares with the SEC.
4,843,300 shares sold at $1.16 per share, a 5% discount to the 10-day VWAP on Nasdaq; closing on October 5, 2026
Approximately $5.6 million gross proceeds; existing shareholder John Paul DeJoria invested an additional $1.0 million
Placement agent Alexander Capital receives a cash fee of about $455,000 (9.0% of gross proceeds) and warrants for 387,464 shares at $1.16, expiring five years after issuance
Company must file a resale registration statement with the SEC within 30 days of the closing
Professional Diversity Network's subsidiary PDN Intelligence entered into a lease, a profit-sharing collaboration and a secured term loan with Goodwill Labs for two NVIDIA B300 eight-GPU systems, with about $1.177 million of initial capital commitments. The filing reports no revenue or profit figures, and the arrangements depend on a single counterparty, Goodwill, and on the equipment being delivered and earning positive profit.
PDN Intelligence buys one system from AMAX for $588,581.99 and leases it to Goodwill Labs; annual base rent is 20% of acquisition cost, about $117,716.
PDN Intelligence lends Goodwill $588,849.23 to finance a second system, bearing no fixed interest and no scheduled principal payments; Goodwill pays 75% of positive distributable profit.
Delivery is expected by January 15, 2027, and the AMAX terms state GPU purchases are final, limiting refund recourse if delivery fails.
The Company paid AMAX $294,291.00 on September 30, 2026, with $294,290.99 payable before shipment.
RPM International reported record first-quarter fiscal 2027 net sales of $2.22 billion, up 4.8%, with diluted EPS of $2.01 and adjusted diluted EPS of $1.98, up 5.3%. The company now expects full-year adjusted EBITDA to grow in the mid-single-digit range, compared with its prior outlook of 5% to 10%, so shareholders face a lower expected profit growth rate despite the strong quarter.
Net sales were $2.22 billion, up 4.8%, with 3.1% organic growth; net income attributable to stockholders was $256.4 million.
Adjusted EBITDA reached a record $405.5 million, up 4.5%; Construction Products Group adjusted EBITDA fell 9.7%.
Full-year fiscal 2027 adjusted EBITDA outlook is mid-single-digit growth, versus the previous 5% to 10%; sales outlook is mid-single-digit, versus the previous 3% to 7%.
Investor day is scheduled for November 9, 2026, at the Stonhard facility in New Jersey.
Barnwell Industries agreed on October 5, 2026 to sell its Canadian oil and natural gas business to 2798913 Alberta Ltd. for a base price of C$9 million, made up of C$4 million in cash and a 5% gross overriding royalty valued at C$5 million. The sale requires approval from holders of a majority of Barnwell's common stock and must close by January 18, 2027, or the agreement can be terminated. The company's board recommends that shareholders vote in favor of the transaction.
Base purchase price of C$9,000,000, including C$4,000,000 in cash and a 5% royalty valued at C$5,000,000
Purchaser paid a C$1,000,000 deposit into escrow at signing, to be credited to the price at closing
Closing requires shareholder approval, and the outside date is January 18, 2027
A buyer affiliate may purchase the royalty for C$5,000,000 after closing, and royalty payments received beforehand do not reduce that price
HighPeak Energy agreed on October 6, 2026 to sell $450 million of convertible preferred stock to two Indonesian investors, with closing expected in the fourth quarter of 2026. The company also obtained an $800 million reserve-based credit facility from Citibank and Fifth Third Bank, which it says will let it repay its existing $1.17 billion term loan in full. The preferred carries a 6.0% cash dividend and a $9.50 conversion price, so it adds a dividend obligation and possible future share issuance for common shareholders.
Investors agreed to buy 450,000 shares of Series A 6.0% Perpetual Convertible Preferred Stock at a $1,000 stated value, for about $450 million in gross proceeds
Preferred convertible into common stock at an initial conversion price of $9.50 per share
New $800 million reserve-based credit facility with Citibank, N.A. and Fifth Third Bank, expected to fund repayment of the $1.17 billion term loan
Each investor may nominate one director; the investment is expected to close in the fourth quarter of 2026, subject to customary conditions
On October 5, 2026, AMC completed a $3.97 billion refinancing that included $2,000 million of 8.875% first lien notes due 2031, an $850 million first lien term loan due 2031, and a $1,120 million second lien term loan at a fixed 11.25% due 2033. The proceeds were used to tender for and redeem AMC's 7.500% Senior Secured Notes due 2029, redeem Muvico's $903.4 million notes due 2029, and repay existing term loans. The company says the deal extends most of its debt maturities and reduces its cost of capital, but the new debt carries higher fixed rates than some of the instruments it replaced, so the net effect for shareholders depends on how the company manages these obligations.
$2,000 million 8.875% first lien notes due October 15, 2031, with semi-annual interest payable April 15 and October 15
$850 million first lien term loans due October 5, 2031, and $1,120 million second lien term loans at a fixed 11.25% due October 5, 2033
Tender offer for AMC Secured Notes: $355,515,000 of the $359,964,500 outstanding (about 98.8%) was tendered, with remaining notes to be redeemed on or about February 15, 2027
Muvico's $903.4 million 2029 senior secured notes to be redeemed in full
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.